The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for groups most at risk and in areas where the burden of HIV remains high.

Newborns exposed to HIV during pregnancy or birth should receive preventive antiretroviral medication immediately after delivery to reduce the risk of transmission from mother to child.

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection. The recommendation, issued at the International AIDS Conference in Kigali,

Freda Jones, founder of LOTUS, empowers women living with HIV in Atlanta through a peer-led support group. Peer support is crucial for HIV care.

A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) among Black women.

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting injectable HIV treatment cabotegravir.

Black women make up just 13% of the U.S. female population, yet they account for over 50% of new HIV diagnoses among women, according to the Kaiser Family Foundation (KFF). That means more than half of all women newly diagnosed with HIV in the U.S. are Black — a staggering statistic that reflects deep-rooted inequalities.

This story was originally published by The Institute for Public Service Reporting Memphis. Healthcare providers across Tennessee are scrambling to find new funding for HIV prevention following the loss of a critical federal grant.

State attorneys general and federal prosecutors alleged Gilead Sciences illegally bankrolled lavish events for prescribers.